Capturing the immunotherapy opportunity in myeloid blood cancers In the fourth quarter of 2025, Mendus presented continued positive long-term survival data of the ADVANCE II trial in acute myeloid leu ...

Like many cancers, acute myeloid leukemia (AML) has been a major beneficiary from the introduction of targeted therapies into the oncology treatment landscape. In fact, 1 of the earliest uses of ...

The American Society of Hematology (ASH) released guidelines on frontline management of acute lymphoblastic leukemia (ALL) in ...

Gyala Therapeutics, a clinical-stage biotechnology company developing innovative cell therapies for hematologic malignancies, ...

Orca Bio, a late-stage biotechnology company committed to transforming the lives of patients through high-precision cell therapy, today announced new clinical data presented at the 2026 Tandem ...

Iclusig, a kinase inhibitor, received a positive opinion for use alongside low-intensity chemotherapy in adults with newly identified disease.

By: Dr. Amrit Kaur Kaler For patients diagnosed with blood cancers such as leukemia, lymphoma, and multiple myeloma, the ...

QTX-2101, an oral arsenic trioxide, received FDA fast track designation for acute promyelocytic leukemia, aiming to simplify ...

An Australian research collaboration has led to a major leap forward in the treatment of acute lymphoblastic leukemia (ALL). Recently published clinical trial results have shown evidence that ...

When doctors told Bendigo Davies he had terminal cancer and only weeks to live, he did not start writing a bucket list or ...

The FDA approved a larger nelarabine vial to improve dosing flexibility and simplify treatment for adult and pediatric ...

HBV coinfection with acute exacerbation was associated with significantly worse survival outcomes in pediatric T-ALL.